Phase 1 N=30 Transporter Cocktail Mutual Interaction
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 A Study of LY2835219 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY2835219 — 3730; 15.4 nanogram*h/milliliter…
Phase 1 N=30 A Single Dose Study of LY3023703 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE — 0; 0; 0; 0 Participants
Phase 1 N=54 A Study for Participants With Advanced Cancer
Advanced Cancer · Metastatic Cancer
Primary: Recommended Dose for Phase 2 Studies — 4.0; 6.0 mg/m²/day
Phase 1 N=15 BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Process for the Determination of the Maximum Tolerated Dose (MTD). — 0; 0; 2 Participants
Phase 1 N=16 Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Type 2 Diabetes Mellitus · Hepatic Impairment
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin — 1413; 1618 ng•hr/mL
Phase 1 N=30 A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
Healthy
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major…
Phase 1 N=127 A Study of Abemaciclib in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) — 3080; 2880; 3110; 3120 Nanograms*hour/milliliter (ng*hr/mL)
Phase 1 N=37 A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Number of Participants With Dose Limiting or Intolerable Treatment Related Adverse Events (AEs) — 0; 0; 0; 0 participants
Phase 1 N=20 A Study of Abemaciclib in Healthy Participants
Healthy
Primary: Mean Time Matched Placebo-Adjusted Changes From Baseline For Fridericia's Corrected QT Interval (ΔΔQTcF) — 1.4; 3.3; 0.2; -2.1 Millisecond (msec)
Phase 1 N=24 A Study of LY2835219 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219 — 134; 10.5 nanogram per milliliter (ng/ml)
Phase 1 N=26 A Study of LY2835219 in Participants With Cancer
Neoplasm · Neoplasm Metastasis
Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of Abemaciclib — 2230; 6850 nanogram*hour/milliliter(mL) ng*h/mL
Phase 1 N=32 First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
Hepatitis B
Primary: Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1 — 4; 3; 2; 3…
Phase 1 N=19 Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib — 0; 0; 1 Participants
Phase 1 N=5 Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 2 Participants